JP2023501377A5 - - Google Patents
Info
- Publication number
- JP2023501377A5 JP2023501377A5 JP2022526120A JP2022526120A JP2023501377A5 JP 2023501377 A5 JP2023501377 A5 JP 2023501377A5 JP 2022526120 A JP2022526120 A JP 2022526120A JP 2022526120 A JP2022526120 A JP 2022526120A JP 2023501377 A5 JP2023501377 A5 JP 2023501377A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- aqueous solution
- stable aqueous
- ravulizumab
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025250896A JP2026048838A (ja) | 2019-11-08 | 2025-12-15 | 高濃度抗ｃ５抗体配合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932674P | 2019-11-08 | 2019-11-08 | |
| US62/932,674 | 2019-11-08 | ||
| US202062992319P | 2020-03-20 | 2020-03-20 | |
| US62/992,319 | 2020-03-20 | ||
| PCT/US2020/058779 WO2021091937A1 (en) | 2019-11-08 | 2020-11-04 | High concentration anti-c5 antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250896A Division JP2026048838A (ja) | 2019-11-08 | 2025-12-15 | 高濃度抗ｃ５抗体配合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501377A JP2023501377A (ja) | 2023-01-18 |
| JP2023501377A5 true JP2023501377A5 (https=) | 2023-11-07 |
Family
ID=73646451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526120A Withdrawn JP2023501377A (ja) | 2019-11-08 | 2020-11-04 | 高濃度抗ｃ５抗体配合物 |
| JP2025250896A Pending JP2026048838A (ja) | 2019-11-08 | 2025-12-15 | 高濃度抗ｃ５抗体配合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250896A Pending JP2026048838A (ja) | 2019-11-08 | 2025-12-15 | 高濃度抗ｃ５抗体配合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230002482A1 (https=) |
| EP (1) | EP4054634A1 (https=) |
| JP (2) | JP2023501377A (https=) |
| WO (1) | WO2021091937A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| EP4281472A1 (en) * | 2021-01-22 | 2023-11-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| CN119454939A (zh) * | 2024-11-28 | 2025-02-18 | 北海康成(苏州)生物制药有限公司 | 一种欧莫扑拜单抗原液及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) * | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
-
2020
- 2020-11-04 WO PCT/US2020/058779 patent/WO2021091937A1/en not_active Ceased
- 2020-11-04 EP EP20816698.3A patent/EP4054634A1/en active Pending
- 2020-11-04 US US17/773,941 patent/US20230002482A1/en active Pending
- 2020-11-04 JP JP2022526120A patent/JP2023501377A/ja not_active Withdrawn
-
2025
- 2025-12-15 JP JP2025250896A patent/JP2026048838A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501377A5 (https=) | ||
| JP2022105625A5 (https=) | ||
| JP2020528894A5 (https=) | ||
| FI3658184T3 (fi) | Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita | |
| TW520291B (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| JP6007316B2 (ja) | 抗体製剤 | |
| Evans et al. | Effect of pseudo-cholinesterase level on action of succinylcholine in man | |
| JP2019526627A (ja) | 抗−ｃｄ３抗体製剤 | |
| US20180142010A1 (en) | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant | |
| EP2376533A1 (en) | Antibody formulation | |
| JP2018521964A (ja) | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 | |
| US11141479B2 (en) | Stable anti-OSMR antibody formulation | |
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| TWI877117B (zh) | 包含掩蔽的抗原結合蛋白質之配製物及藥物組成物 | |
| JP2023507053A (ja) | 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用 | |
| Roberts et al. | Fatal outcome from administration of a salt emetic | |
| WO2025031279A1 (zh) | 一种高浓度高稳定性的抗体制剂及其制备方法 | |
| Szczepańska et al. | Addison's disease with hypofunction of the parathyroid glands | |
| WO2018059193A1 (zh) | 一种稳定的重组人血管内皮抑制素皮下注射组合物 | |
| Gupta et al. | Transfusion related acute lung injury with intravenous immunoglobulin | |
| JP2002522507A (ja) | 疾患状態の処置 | |
| Rimal et al. | Small volume plasma exchange as an alternative to conventional plasma exchange and intravenous immunoglobulin for myasthenic crisis: a case report | |
| JP7630625B2 (ja) | 改善された凍結乾燥製剤 | |
| Drew et al. | Failure of muscular dystrophy treatment with a protein hydrolysate | |
| Kaenkumchorn et al. | P-36: Use of Intravenous Iron Sucrose in Pediatric Intestinal Failure Patients |